Hypernociception induced by TLR agonists and the NY-ESO-1 vaccine formulations.

<p>(<b>A</b>) Different TLR agonists were injected in the footpad of mice and hypernociception evaluated at the indicated time points. (<b>B</b>) Vaccine formulations containing alum; alum plus NY-ESO-1; or alum plus NY-ESO-1 associated with TLR agonists were given to mice that were left untreated or treated with PCM orally, 30 minutes prior injection with different vaccine formulations. Asterisks mean significant difference when comparing PBS group with TLR agonists experimental groups (<i>P</i><0,05).</p>